The Senate Special Committee on Aging is holding a series of hearings investigating sudden price increases for drugs that go off-patent.
“For many decades, federal policy has sought to strike the right balance between maintaining the incentives needed to promote innovation and the development of new drugs and keeping medicines affordable,” chair Susan Collins (R, Me) said in a statement at the first hearing (http://1.usa.gov/1YZGjnG). “That balance we have struck never anticipated companies acquiring off-patent drugs and then jacking up their prices to enormous heights….”
Rita Rubin. Senate Committee Investigates Price Hikes for Off-Patent Drugs. JAMA. 2016;315(6):549. doi:10.1001/jama.2016.0162